Enfusion, Inc. (NYSE:ENFN) Shares Sold by T. Rowe Price Investment Management Inc.

by · The Markets Daily

T. Rowe Price Investment Management Inc. reduced its holdings in Enfusion, Inc. (NYSE:ENFN – Free Report) by 12.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,157,248 shares of the company’s stock after selling 169,579 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 0.90% of Enfusion worth $11,920,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. New York State Common Retirement Fund lifted its holdings in Enfusion by 23.8% in the 4th quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock valued at $19,848,000 after purchasing an additional 370,498 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Enfusion by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 1,050,549 shares of the company’s stock valued at $10,823,000 after purchasing an additional 21,183 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Enfusion by 6.1% in the 4th quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company’s stock valued at $10,671,000 after purchasing an additional 59,700 shares in the last quarter. Impax Asset Management Group plc lifted its holdings in Enfusion by 31.5% in the 4th quarter. Impax Asset Management Group plc now owns 890,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 213,052 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Enfusion by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 798,870 shares of the company’s stock valued at $8,229,000 after purchasing an additional 110,364 shares in the last quarter. 81.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Enfusion news, insider Bronwen Bastone sold 3,126 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $35,573.88. Following the completion of the sale, the insider now owns 221,875 shares in the company, valued at $2,524,937.50. This represents a 1.39 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Neal Pawar sold 2,769 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $31,788.12. Following the completion of the sale, the chief operating officer now owns 1,231,627 shares of the company’s stock, valued at approximately $14,139,077.96. The trade was a 0.22 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,223 shares of company stock worth $754,778. Corporate insiders own 36.44% of the company’s stock.

Enfusion Trading Up 0.5 %

Enfusion stock opened at $10.85 on Monday. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80. The stock has a 50 day moving average of $11.06 and a 200-day moving average of $10.50. The stock has a market cap of $1.40 billion, a P/E ratio of 271.29, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN – Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, equities analysts predict that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, William Blair reiterated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th.

Check Out Our Latest Report on ENFN

About Enfusion

(Free Report)

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.

Read More

Want to see what other hedge funds are holding ENFN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enfusion, Inc. (NYSE:ENFN – Free Report).